Chemical Modifications and Solid-Phase Synthesis of Oligonucleotide Therapeutics

Why Natural Nucleic Acids Need Chemical Design

Oligonucleotide therapeutics such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are built around a simple biological idea: short nucleic acid sequences can recognize RNA targets through base pairing and modulate gene expression. That idea is powerful, but natural nucleic acids are not automatically drug-like molecules.

Unmodified RNA and DNA face several practical barriers in biological environments. They can be degraded by nucleases. They are highly charged and hydrophilic, which limits passive membrane crossing. They may show poor tissue exposure without a delivery strategy. They may also interact with immune-sensing pathways if the sequence, chemistry or formulation is not carefully designed.

For this reason, modern oligonucleotide development is not only sequence selection. It is chemical engineering at the molecular level. Developers adjust the phosphate backbone, sugar ring, nucleobase and terminal groups to improve stability, binding, pharmacokinetics, delivery compatibility and manufacturability. These modifications are then translated into real materials through modified nucleosides, phosphoramidite monomers, linkers, solid supports and controlled solid-phase synthesis.

For chemistry suppliers and development partners, the key point is practical: an oligonucleotide program depends on reliable access to high-quality modified building blocks. A 2'-modified nucleoside, a GalNAc linker, a cholesterol modifier, a CPG support or a specialty phosphoramidite is not just a reagent. It can determine whether downstream synthesis, purification and analytical confirmation proceed smoothly.

The Basic Nucleotide Architecture

A nucleotide contains three parts: a phosphate group, a pentose sugar and a nucleobase. The nucleobase carries the recognition information. The sugar provides the structural platform. The phosphate connects one nucleotide to the next and creates the negatively charged backbone.

In a nucleic acid chain, the 3' hydroxyl of one nucleotide connects to the 5' phosphate of the next nucleotide through a phosphodiester linkage. This natural linkage is often abbreviated as PO. The PO backbone supports normal biological functions such as replication, transcription, translation and molecular recognition.

For therapeutic oligonucleotides, however, natural PO linkages can be vulnerable. Nucleases recognize and cleave nucleic acid backbones. If an oligonucleotide is degraded before it reaches the intended tissue or cellular compartment, target engagement will be limited. Backbone modification is therefore one of the earliest and most important strategies in oligonucleotide medicinal chemistry.

Backbone Modification: PO and PS Linkages

The most widely known backbone modification is phosphorothioate (PS). In a PS linkage, one non-bridging oxygen atom in the phosphate group is replaced by sulfur. This small atomic substitution has major consequences. It can improve resistance to nuclease degradation and alter interactions with plasma and tissue proteins, which may influence distribution and pharmacokinetic behavior.

PS modification is especially important in many ASO designs. Single-stranded ASOs often need to remain stable long enough to find and bind target RNA. PS linkages help protect the molecule and can improve systemic exposure. In gapmer ASOs, PS backbones are commonly combined with sugar-modified wing regions and a central DNA-like gap.

PS is not a simple "more is always better" modification. Introducing sulfur creates chirality at phosphorus, generating Rp and Sp diastereomers. A sequence with multiple PS linkages can therefore exist as a complex mixture of stereochemical forms unless stereocontrolled chemistry is used. PS content and placement may also affect protein binding, potency, tolerability and analytical complexity.

In siRNA, PS modification is often used more selectively. siRNA functions as a duplex and must interact with the RNA-induced silencing complex (RISC). Excessive modification can interfere with strand loading or gene-silencing activity. Many siRNA designs use PS linkages near termini or selected positions to improve nuclease resistance while preserving RNAi function.

Sugar Modifications: Why the 2' Position Matters

The pentose sugar is not just a passive scaffold. It influences the geometry, stability and enzyme recognition of the oligonucleotide. The 2' position is especially important because it sits close to the backbone and differs between RNA and DNA.

RNA contains a 2'-OH group. DNA contains a 2'-H. The 2'-OH makes RNA chemically and biologically more reactive. It can influence backbone cleavage and nuclease recognition. Replacing or modifying the 2' group is therefore a central strategy for improving oligonucleotide stability and function.

2'-O-Methyl

2'-O-methyl (2'-OMe) replaces the 2'-OH with a 2'-OCH3 group. This is one of the most established sugar modifications. It can improve nuclease resistance and is often used to reduce unwanted immune stimulation. 2'-OMe appears in both ASO and siRNA designs.

From a building-block perspective, 2'-OMe chemistry is mature, but quality still matters. The modified nucleoside must be converted into a phosphoramidite form suitable for solid-phase synthesis, with appropriate protecting groups and moisture control.

2'-Fluoro

2'-fluoro (2'-F) replaces the 2'-OH with fluorine. It is common in siRNA designs and can improve stability while supporting strong pairing with target RNA. Many siRNA modification patterns combine 2'-F and 2'-OMe to balance potency, stability and tolerability.

2'-F phosphoramidites may behave differently from other monomers during synthesis. Coupling efficiency, protecting-group compatibility and impurity control should be evaluated during process development.

2'-O-Methoxyethyl

2'-O-methoxyethyl (2'-MOE) contains a larger side chain than 2'-OMe. It is particularly important in ASO medicinal chemistry, especially in gapmer designs where modified wing regions improve binding and stability while a central DNA-like gap supports RNase H activity.

2'-MOE monomers are more structurally demanding than simple natural nucleosides. Their synthesis, purification and conversion into phosphoramidite building blocks require careful route design.

Locked Nucleic Acid

Locked nucleic acid (LNA) uses a bridge between the 2' and 4' positions to lock the sugar into a favorable conformation. LNA can strongly increase binding affinity to complementary RNA. This can be useful, but placement and number of LNA units must be carefully controlled. Strong binding can be beneficial in one design and problematic in another.

Base Modifications and Terminal Modifications

Base modifications tune the "letters" of the nucleic acid. They can influence pairing, stability, translation behavior and immune recognition. Examples include 5-methylcytosine, pseudouridine and N1-methylpseudouridine. In short oligonucleotides, base modifications may support recognition or stability. In mRNA, modified nucleoside triphosphates such as pseudouridine triphosphate or N1-methylpseudouridine triphosphate are widely discussed because they can affect translation and innate immune sensing.

Terminal modifications serve different purposes. A 5' phosphate may be important for certain RNAi designs. Fluorescent dyes such as Cy3 or Cy5 support tracking and assay development. Biotin supports capture or detection. Cholesterol can alter binding or delivery behavior. GalNAc can support liver-targeted delivery through ASGPR-mediated uptake. At the 3' end, inverted dT, spacers, biotin, cholesterol or other solid-support-based modifications may improve stability, add functionality or support conjugation.

Terminal modifications are often supplied as modifiers or functionalized solid supports rather than ordinary nucleoside phosphoramidites. This distinction matters for sourcing and process planning. A sugar-modified nucleoside is often incorporated as a modified phosphoramidite monomer. A 3' terminal modifier may require a special CPG support. A PS linkage is typically introduced during the synthesis cycle through sulfurization rather than by using a "PS monomer" for every position.

ASO and siRNA Use Different Design Logic

ASO and siRNA are both oligonucleotide modalities, but their design logic is different.

Many ASOs are single-stranded and bind target RNA directly. Gapmer ASOs typically contain a central DNA-like gap flanked by modified wing regions. The gap supports RNase H recruitment, while the wings improve binding and stability. 2'-MOE, 2'-OMe and LNA are common wing-region modifications depending on the program.

siRNA is a double-stranded system. It contains a guide strand and a passenger strand. After cellular uptake, the guide strand is loaded into RISC and directs recognition of the target mRNA. siRNA modification must therefore balance stability with RISC loading, strand selection, target recognition and delivery compatibility. A modification pattern that works well for an ASO may not be suitable for an siRNA duplex.

Phosphoramidite Monomers: Turning Modifications into Building Blocks

A modified nucleoside is not automatically ready for oligonucleotide synthesis. For standard solid-phase synthesis, it usually needs to be converted into a protected nucleoside phosphoramidite monomer. This makes the molecule compatible with automated coupling cycles.

A typical phosphoramidite monomer includes several design features:

• A protected 5' hydroxyl, often with a DMT group
• A 3' phosphoramidite reactive site for coupling
• Protected nucleobase functional groups when needed
• Appropriate 2' protection or modification for RNA-related chemistry
• Sufficient purity, dryness and stability for synthesis use

In simple terms, a phosphoramidite monomer is the building block. Coupling is the action that attaches that building block to the growing oligonucleotide chain. Solid-phase synthesis is the repeated sequence of actions that builds the full chain.

This distinction is important for custom synthesis projects. A customer may ask for "2'-OMe," "GalNAc," "cholesterol," or "LNA," but the actual supply form depends on how it will be used. It may need to be a phosphoramidite monomer, a terminal modifier, an activated linker, a CPG support or an intermediate used before final conversion.

How Solid-Phase Oligonucleotide Synthesis Works

Solid-phase phosphoramidite synthesis is the most established method for preparing many ASO and siRNA strands. The first nucleoside is attached to an insoluble solid support, commonly controlled pore glass (CPG). The chain is then extended through repeated synthesis cycles.

The synthesis direction in chemical solid-phase synthesis is often described as 3' to 5'. The first nucleoside is attached through its 3' end to the support. The 5' hydroxyl is protected. Each cycle removes the 5' protecting group, exposes the 5'-OH, and attaches the next phosphoramidite monomer.

The core cycle contains four steps:

1. Detritylation: removal of the 5'-DMT protecting group to expose the 5'-OH.
2. Coupling: reaction of the activated phosphoramidite monomer with the exposed 5'-OH.
3. Capping: blocking of unreacted 5'-OH groups to prevent deletion sequences from continuing.
4. Oxidation or sulfurization: conversion of the unstable phosphite triester intermediate into a stable PO or PS linkage.

After all cycles are complete, the oligonucleotide is cleaved from the support and globally deprotected. The crude product is then purified and analyzed. Common impurities include truncated sequences, extended sequences, deprotection-related products, PO/PS-related species, salts and residual small molecules.

Why Modified Building Blocks Matter for Process Development

Solid-phase synthesis is stepwise. Even small inefficiency at each cycle accumulates across the sequence. Modified monomers can introduce additional challenges because they may couple more slowly, show different solubility, contain sensitive protecting groups, or generate unique impurities. A bulky terminal modifier or ligand can create still more difficulty.

For process development, building-block quality affects more than the incoming raw material specification. It can influence coupling yield, impurity profile, purification difficulty and batch-to-batch comparability. A modified phosphoramidite with residual moisture or decomposition products may reduce coupling efficiency. A terminal GalNAc or cholesterol modifier with related impurities may produce difficult-to-separate conjugate species. A functionalized solid support with inconsistent loading may affect final yield.

This is why custom synthesis and analytical support are important in oligonucleotide-related programs. The most useful supplier conversation starts with the intended use. Is the material for early screening, route scouting, lead optimization, analytical standard preparation or larger development supply? Each stage may require a different balance of speed, purity, documentation and scale.

mRNA Uses a Different Raw-Material Logic: NTPs and IVT

ASO and siRNA strands are often made through solid-phase phosphoramidite synthesis because their sequences are relatively short. mRNA is different. It is much longer, often hundreds to thousands of nucleotides, so it is usually produced by in vitro transcription (IVT) rather than stepwise solid-phase synthesis.

In IVT, RNA polymerase reads a DNA template and incorporates nucleoside triphosphates (NTPs) into the growing RNA chain. The four standard NTPs are ATP, UTP, CTP and GTP. Modified mRNA can be produced by replacing part or all of a standard NTP with a modified NTP, such as pseudouridine triphosphate or N1-methylpseudouridine triphosphate.

This distinction matters commercially and technically. Short oligonucleotide programs often depend on modified nucleoside phosphoramidites, terminal modifiers and solid supports. mRNA programs often depend on NTPs, modified NTPs, capping reagents, enzymes, template quality and purification systems. The raw-material logic is related, but not identical.

How CHEMOS Supports Oligonucleotide-Related Chemistry

CHEMOS supports custom synthesis, route development, process optimization and analytical support for complex molecular building blocks used in advanced pharmaceutical and biotechnology research. For oligonucleotide-related programs, this can include modified nucleosides, protected intermediates, phosphoramidite-related materials, terminal modifiers, linkers, PEG spacers, GalNAc-related building blocks, cholesterol-related modifiers and other functional materials.

For early discovery, CHEMOS can help prepare small batches of specialty structures for screening or feasibility evaluation. For process development, CHEMOS can support route review, impurity understanding, analytical documentation and scale-up planning for selected intermediates or building blocks. For customers developing oligonucleotide, conjugation or delivery-related projects, reliable upstream chemistry can make downstream synthesis and analysis more predictable.

CHEMOS does not need to position itself as a finished oligonucleotide drug-product manufacturer to contribute meaningfully to this field. The more relevant role is as a chemistry partner for the specialized materials that enable oligonucleotide synthesis, modification and delivery research.

FAQ

What is the difference between a nucleoside and a nucleotide?

A nucleoside contains a nucleobase and a sugar. A nucleotide contains a nucleobase, sugar and phosphate group. Oligonucleotide chains are built from nucleotide units connected through phosphate linkages.

What is a phosphorothioate modification?

A phosphorothioate modification replaces one non-bridging oxygen in the phosphate backbone with sulfur. This can improve nuclease resistance and alter protein-binding behavior, but it also adds stereochemical and analytical complexity.

Why are 2' sugar modifications important?

The 2' position influences RNA stability, conformation and nuclease recognition. Modifications such as 2'-OMe, 2'-F, 2'-MOE and LNA can improve stability, affinity or biological performance depending on placement.

Are ASO and siRNA modified in the same way?

No. ASO and siRNA have different mechanisms. Gapmer ASOs often use modified wings and a central DNA-like gap for RNase H recruitment. siRNA must preserve duplex behavior, guide-strand loading and RISC-mediated silencing.

What is a nucleoside phosphoramidite monomer?

A nucleoside phosphoramidite monomer is a protected building block designed for solid-phase oligonucleotide synthesis. It carries the reactive chemistry needed for coupling to a growing chain.

How does solid-phase synthesis introduce PS linkages?

After coupling, the linkage is initially a phosphite triester intermediate. Oxidation produces a PO linkage, while sulfurization produces a PS linkage. PS is therefore often introduced during the synthesis cycle.

How is mRNA production different from ASO or siRNA synthesis?

ASO and siRNA strands are commonly made by solid-phase phosphoramidite synthesis. mRNA is usually produced by in vitro transcription using NTPs or modified NTPs and an RNA polymerase.

Can CHEMOS support custom modified nucleoside or phosphoramidite-related projects?

Yes. CHEMOS can review target structures and support custom synthesis, route development and analytical documentation for modified nucleosides, phosphoramidite-related materials, terminal modifiers, linkers and related building blocks.

Notice

This article is for research and technical information purposes only. It is not intended as medical, regulatory or legal advice. Materials and technologies discussed should be used according to applicable research-use, safety and regulatory requirements.

References and Further Reading

1. Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery, 2021. https://doi.org/10.1038/s41573-021-00162-z
2. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery, 2019. https://doi.org/10.1038/s41573-019-0017-4
3. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 2020. https://doi.org/10.1038/s41573-020-0075-7
4. Wan WB, Seth PP. The medicinal chemistry of therapeutic oligonucleotides. Journal of Medicinal Chemistry, 2016. https://doi.org/10.1021/acs.jmedchem.6b00551
5. Beaucage SL, Caruthers MH. Deoxynucleoside phosphoramidites: A new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Letters, 1981, 22(20), 1859-1862.
6. Beaucage SL, Iyer RP. Advances in the synthesis of oligonucleotides by the phosphoramidite approach. Tetrahedron, 1992, 48(12), 2223-2311.
7. Reese CB. Oligo- and poly-nucleotides: 50 years of chemical synthesis. Organic & Biomolecular Chemistry, 2005. https://doi.org/10.1039/B510458K
8. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005. https://doi.org/10.1016/j.immuni.2005.06.008